Clinical Trials Directory

Trials / Completed

CompletedNCT01754987

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
5 (actual)
Sponsor
Thomas Jefferson University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to assess overall tumor response rate and evaluate disease progression

Detailed description

Intravenous Ascorbic Acid (Vitamin C) is a widely used alternative cancer treatment. This trial will study an intravenous Vitamin C treatment for persons with liver cancer that has spread, who are also receiving Sorafenib (a standard cancer drug), to see whether the combination of Vitamin C and Sorafenib is safe and well tolerated. Phase I will involve 6 persons who will receive the Vitamin C for 8 weeks to more specifically assess the safety of getting Vitamin C in combination with Sorafenib. Phase II will be randomized to receive either Vitamin C plus Sorafenib or Sorafenib alone for 16 weeks. If Vitamin C has a beneficial effect on tumour cells, patients may experience a regression of tumor or tumor markers. Additional benefits include scans at no charge to the patient.

Conditions

Interventions

TypeNameDescription
DRUGAscorbic Acid + Sorafenib
DRUGSorafenib

Timeline

Start date
2012-09-01
Primary completion
2016-01-01
Completion
2016-01-01
First posted
2012-12-21
Last updated
2025-05-04
Results posted
2018-08-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01754987. Inclusion in this directory is not an endorsement.